首页> 外文期刊>Archives of disease in childhood >Genetic testing in children with surfactant dysfunction
【24h】

Genetic testing in children with surfactant dysfunction

机译:表面活性剂功能障碍儿童的基因检测

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives: To present the UK experience in genetic diagnoses of surfactant protein dysfunction disorders and develop a referral algorithm for neonates and children with persistent respiratory problems. Materials and methods: Between 2006 and 2011, 427 cases were referred for surfactant mutation analyses to the North East Thames Regional Molecular Genetics Laboratory at Great Ormond Street Hospital, London. The results were reviewed and referring physicians of mutation positive cases contacted to complete a questionnaire providing clinical, radiological, histological and outcome information. Results: 25 new cases were found to have genetic mutations for surfactant dysfunction disorders (7.5%), with six resulting in surfactant protein B dysfunction, seven surfactant protein C dysfunction and 12 ATP-binding cassette subfamily A member 3 (ABCA3) dysfunction. The referrals were from 15 different paediatric centres. In addition, three affected surfactant protein B (SFTPB) cases were prenatal diagnoses, following the birth of previously affected children. The majority of the con firmed cases (23 of 25) were born after 37 weeks gestation. All children with SFTPB dysfunction and the majority of ABCA3 patients presented with respiratory distress at birth. All SFTPB cases died from intractable respiratory failure. The outcome for ABCA3 mutations was variable with seven survivors. The clinical and radiological presentation of surfactant protein C (SFTPC) patients suggested mainly interstitial lung process with the majority surviving on medication. Conclusions: Surfactant mutation analysis is now well established in the UK and allows better genetic diagnosis and counselling. The rarity of the condition makes it difficult to develop a validated algorithm for genetic evaluation with a need for international networking. Referrals need to be rationalised for the service to be time and cost effective.
机译:目的:介绍英国在表面活性剂蛋白功能障碍疾病的遗传学诊断方面的经验,并为患有持续呼吸问题的新生儿和儿童制定转诊算法。材料和方法:2006年至2011年,伦敦大奥蒙德街医院的东北泰晤士河区域分子遗传学实验室将427例病例进行了表面活性剂突变分析。审查结果并联系突变阳性病例的转诊医生,以完成一份问卷,提供临床,放射学,组织学和结果信息。结果:发现25例具有表面活性剂功能障碍基因突变的新突变(7.5%),其中6例导致表面活性剂蛋白B功能障碍,7例表面活性剂蛋白C功能障碍和12个ATP结合盒亚家族A成员3(ABCA3)功能障碍。转诊来自15个不同的儿科中心。此外,三例受影响的表面活性蛋白B(SFTPB)病例在先前患病的孩子出生后进行了产前诊断。大多数确诊病例(25例中的23例)是在妊娠37周后出生的。所有患有SFTPB功能障碍的儿童和大多数ABCA3患者在出生时均出现呼吸窘迫。所有SFTPB病例均因顽固性呼吸衰竭而死亡。 ABCA3突变的结果因七个幸存者而异。表面活性剂蛋白C(SFTPC)患者的临床和影像学表现提示主要是间质性肺过程,而大多数患者仍依靠药物生存。结论:表面活性剂突变分析目前在英国已经建立,可以更好地进行基因诊断和咨询。这种病的稀有性使得难以开发需要国际联网的遗传评估验证算法。为了使服务具有时间和成本效益,需要对转诊进行合理化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号